# Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery

> **NCT00478140** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 4 (actual)

## Conditions studied

- Adenocarcinoma of the Extrahepatic Bile Duct
- Adenocarcinoma of the Gallbladder
- Malignant Neoplasm
- Recurrent Extrahepatic Bile Duct Cancer
- Recurrent Gallbladder Cancer
- Unresectable Extrahepatic Bile Duct Cancer
- Unresectable Gallbladder Cancer

## Interventions

- **BIOLOGICAL:** trastuzumab
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00478140
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-05
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Due to slow accrual
- **Last updated:** 2019-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00478140

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00478140, "Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00478140. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*